A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity

Cancer Immunology, Immunotherapy

Volumn 53, Issue 4, 2004, Pages 345-357

  Card, Kimberlyn F ^a   Price Schiavi, Shari A ^a   Liu, Bai ^a   Thomson, Elizabeth ^a   Nieves, Esperanza ^b   Belmont, Heather ^a   Builes, Janette ^a   Jiao, Jin An ^f   Hernandez, Javier ^c   Weidanz, Jon ^d   Sherman, Linda ^c   Francis, John L ^e   Amirkhosravi, Ali ^e   Wong, Hing C ^a  

^a ALTOR BIOSCIENCE CORPORATION   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^f Hematech Incorporated   (United States)

Author keywords

Cytokines; Molecular biology; T cell receptors; Tumor immunity

Indexed keywords

CYTOKINE; EPITOPE; FUSION PROTEIN 264S; HLA A2 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2; PROTEIN P53; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR INTERLEUKIN 2 FUSION PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CHO CELL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LUNG METASTASIS; LYMPHOBLAST; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TRANSGENIC MOUSE; TUMOR IMMUNITY; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; FEMALE; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12144290526     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0450-3     Document Type: Article

References (56)

1. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94
2. Anderson KS, Alexander J, Wei M, Cresswell P (1993) Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol 151:3407
3. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397
4. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA (1996) Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98:2801
5. Chung S, Wucherpfennig KW, Friedman SM, Hafler DA, Strominger JL (1994) Functional three-domain single-chain T-cell receptors. Proc Natl Acad Sci USA 91:12654
6. Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203
7. Dummer R, Gore ME, Hancock BW, Guillou PJ, Grobben HC, Becker JC, Oskam R, Dieleman JP, Burg G (1995) A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer 75:1038
8. Engel I, Ottenhoff TH, Klausner RD (1992) High-efficiency expression and solubilization of functional T cell antigen receptor heterodimers. Science 256:1318
9. Gregoire C, Rebai N, Schweisguth F, Necker A, Mazza G, Auphan N, Millward A, Schmitt-Verhulst AM, Malissen B (1991) Engineered secreted T-cell receptor alpha beta heterodimers. Proc Natl Acad Sci USA 88:8077
10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823
11. Grussenmeyer T, Scheidtmann KH, Hutchinson MA, Eckhart W, Walter G (1985) Complexes of polyoma virus medium T antigen and cellular proteins. Proc Natl Acad Sci USA 82:7952
12. Hank JA, Albertini MR, Schiller J, Sondel PM (1993) Activation of multiple effector mechanisms to enhance tumor immunotherapy. J Immunother 14:329
13. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM (1990a) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234
14. Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM (1990b) Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J Biol Response Mod 9:5
15. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M, et al (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15:29
16. Harvill ET, Morrison SL (1995) An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1:95
17. Harvill ET, Fleming JM, Morrison SL (1996) In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J Immunol 157:3165
18. Hilyard KL, Reyburn H, Chung S, Bell JI, Strominger JL (1994) Binding of soluble natural ligands to a soluble human T-cell receptor fragment produced in Escherichia coli. Proc Natl Acad Sci USA 91:9057
19. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER., Vogelstein B, Levine AJ (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1:571
20. Hurford RK Jr, Dranoff G, Mulligan RC, Tepper RI (1995) Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet 10:430
21. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879
22. Iggo R, Gatter K, Bartek J, Lane D, Harris AL (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675
23. Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD, Sondel PM (1999) Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 48:219
24. Klausner RD, Lippincott-Schwartz J, Bonifacino JS (1990) The T cell antigen receptor: insights into organelle biology. Annu Rev Cell Biol 6:403
25. Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, Ernstoff MS (2001) Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/ neu. J Immunol Methods 248:149
26. Lin AY, Devaux B, Green A, Sagerstrom C, Elliott JF, Davis MM (1990) Expression of T cell antigen receptor heterodimers in a lipid-linked form. Science 249:677
27. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA (1997) Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89:1586
28. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706
29. Lustgarten J, Marks J, Sherman LA (1999) Redirecting effector T cells through their IL-2 receptors. J Immunol 162:359
30. McLaughlin R, O'Hanlon D, McHale T, Connolly CE, Given HF (2001) Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer. Ir J Med Sci 170:11
31. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4:1183
32. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L (2001) Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 19:1312
33. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697
34. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399
35. Peng LS, Penichet ML, Morrison SL (1999) A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 163:250
36. Penichet ML, Harvill ET, Morrison SL (1997) Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies 8:106
37. Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ (1999) A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother 22:371
38. Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS (1999) A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother 48:9
39. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, et al (2001) Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33:433
40. Rosenberg SA, Spiess PJ, Schwarz S (1983) In vivo administration of interleukin-2 enhances specific alloimmune responses. Transplantation 35:631
41. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889
42. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474
43. Rosenberg SA, Yang JC, White DE, Steinberg SM (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228:307
44. Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, Marincola FM, Parkinson DR, Schwartzentruber DJ, Topalian SL, et al. (1996) Correlates of Response to IL-2 Therapy in Patients Treated for Metastatic Renal Cancer and Melanoma. Cancer J Sci Am 2:91
45. Sherman LA, Hesse SV, Irwin MJ, La Face D, Peterson P (1992) Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258:815
46. Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B (1988) Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 48:2561
47. Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. (1991) Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma. Cancer Invest 9:35
48. Temmim L, Baker H. Sinowatz F (2001) Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Anticancer Res 21:743
49. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993
50. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833
51. Thor Straten P, Guldberg P, Schrama D, Andersen MA, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC (2001) In situ cytokine therapy: redistribution of clonally expanded T cells. Eur J Immunol 31:250
52. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359
53. van Golen KL, Risin S, Staroselsky A, Berger D, Tainsky MA, Pathak S, Price JE (1996) Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clin Exp Metastasis 14:95
54. Weber S, Traunecker A, Oliveri F, Gerhard W, Karjalainen K (1992) Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 356:793
55. Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM (1990) Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res 50:2683
56. Wiebke EA, Rosenberg SA, Lotze MT (1988) Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 6:1440